Prenetics Global Limited(PRE)Earnings, Financials & Key Ratios
PRE•NASDAQ
$15.90
$242M mkt cap·Price updated May 6, 2026
AboutPrenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.Show more
- Revenue$92M+201.7%
- EBITDA-$34M+20.4%
- Net Income-$58M-26.0%
- EPS (Diluted)-4.15-14.0%
- Gross Margin52.98%+5.3%
- EBITDA Margin-36.37%+73.6%
- Operating Margin-40.46%+74.3%
- Net Margin-63.13%+58.3%
- ROE-33.73%-38.9%
- ROIC-20.81%+15.9%
- Debt/Equity0.01-62.5%
- Interest Coverage-155.12+34.6%
PRE Key Insights
Prenetics Global Limited (PRE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 82 (top 18%)
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 10.6% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PRE Price & Volume
Prenetics Global Limited (PRE) stock price & volume — 10-year historical chart
Loading chart...
PRE Growth Metrics
Prenetics Global Limited (PRE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years7.23%
3 Years91.46%
TTM171.69%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM0.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM10.78%
Return on Capital
10 Years-45.77%
5 Years-39.88%
3 Years-22.63%
Last Year-21.19%
PRE Recent Earnings
Prenetics Global Limited (PRE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (64%)●Beat Revenue 4/12 qtrs (36%)
Q1 2026Latest
Feb 18, 2026EPS
$0.27
Est $0.49
+44.9%
Revenue
$37M
Est $33M
+9.5%
Q4 2025
Nov 10, 2025EPS
$0.41
Est $0.55
+25.5%
Revenue
$24M
Est $38M
-38.5%
Q4 2025
Sep 12, 2025EPS
$0.82
Est $0.71
-15.5%
Revenue
$18M
Est $22M
-18.5%
Q3 2025
Aug 22, 2025EPS
$0.80
Revenue
$17M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 18, 2026 | $0.27vs $0.49+44.9% | $37Mvs $33M+9.5% |
| Q4 2025 | Nov 10, 2025 | $0.41vs $0.55+25.5% | $24Mvs $38M-38.5% |
| Q4 2025 | Sep 12, 2025 | $0.82vs $0.71-15.5% | $18Mvs $22M-18.5% |
| Q3 2025 | Aug 22, 2025 | $0.80 | $17M |
Based on last 12 quarters of dataView full earnings history →
PRE Peer Comparison
Prenetics Global Limited (PRE) competitors in Point-of-Care and Rapid Testing — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 CSTL | 749.83M | 24.75 | -29.82 | 3.66% | -3.77% | -2.77% | 0.08 | |
 QDEL | 746.18M | 10.96 | -0.66 | -1.89% | -45.57% | -56.31% | 1.46 | |
 AHCO | 1.55B | 11.41 | -21.93 | -0.49% | -2.78% | -5.09% | 1.25 | |
 HIMS | 6.94B | 26.88 | 52.71 | 59% | 5.47% | 23.73% | 2.07 | |
 MYRG | 7.08B | 454.78 | 60.40 | 8.79% | 3.71% | 22.14% | 0.16 | |
 TMO | 175.76B | 472.95 | 26.66 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare PRE vs Peers
Prenetics Global Limited (PRE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRE Income Statement
Prenetics Global Limited (PRE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 9.23M | 65.18M | 12.53M | 13.16M | 21.74M | 30.62M | 92.39M | 69.04M |
| Revenue Growth % | - | 605.93% | -80.77% | 5.04% | 65.17% | 40.83% | 201.72% | 171.69% |
| Cost of Goods Sold | 6.52M | 38.83M | 8.93M | 9.55M | 12.91M | 15.22M | 43.45M | 36.48M |
| COGS % of Revenue | 70.59% | 59.58% | 71.25% | 72.52% | 59.39% | 49.71% | 47.02% | - |
| Gross Profit | 2.72M▲ 0% | 26.34M▲ 870.2% | 3.6M▼ 86.3% | 3.62M▲ 0.4% | 8.83M▲ 144.1% | 15.4M▲ 74.4% | 48.94M▲ 217.8% | 32.56M▲ 0% |
| Gross Margin % | 29.41% | 40.42% | 28.75% | 27.48% | 40.61% | 50.29% | 52.98% | 47.16% |
| Gross Profit Growth % | - | 870.24% | -86.33% | 0.43% | 144.05% | 74.41% | 217.82% | - |
| Operating Expenses | 23.52M | 27.34M | 60.26M | 69.64M | 60.74M | 63.54M | 86.33M | 75.99M |
| OpEx % of Revenue | 254.72% | 41.95% | 480.86% | 529.02% | 279.34% | 207.52% | 93.44% | - |
| Selling, General & Admin | 17.96M | 23.11M | 53.67M | 64.08M | 49.68M | 55.37M | 81.2M | 70.41M |
| SG&A % of Revenue | 194.46% | 35.45% | 428.24% | 486.79% | 228.5% | 180.81% | 87.88% | - |
| Research & Development | 2.99M | 2.78M | 6.39M | 5.99M | 11.66M | 10.92M | 5.13M | 7.38M |
| R&D % of Revenue | 32.38% | 4.27% | 51% | 45.5% | 53.64% | 35.67% | 5.55% | - |
| Other Operating Expenses | 2.57M | 1.45M | 202.18K | -430K | -606.84K | -2.75M | 0 | -1.51M |
| Operating Income | -20.8M▲ 0% | -995.13K▲ 95.2% | -56.66M▼ 5593.9% | -66.02M▼ 16.5% | -51.91M▲ 21.4% | -48.14M▲ 7.2% | -37.38M▲ 22.3% | -43.43M▲ 0% |
| Operating Margin % | -225.31% | -1.53% | -452.11% | -501.53% | -238.73% | -157.23% | -40.46% | -62.91% |
| Operating Income Growth % | - | 95.22% | -5593.94% | -16.52% | 21.38% | 7.25% | 22.35% | - |
| EBITDA | -18.57M | 1.43M | -49.32M | -58.48M | -44.11M | -42.22M | -33.6M | -53.51M |
| EBITDA Margin % | -201.11% | 2.2% | -393.49% | -444.23% | -202.88% | -137.86% | -36.37% | -77.51% |
| EBITDA Growth % | - | 107.71% | -3546.42% | -18.58% | 24.57% | 4.3% | 20.4% | -34.21% |
| D&A (Non-Cash Add-back) | 2.23M | 2.43M | 7.35M | 7.54M | 7.79M | 5.93M | 3.78M | 0 |
| EBIT | -20.8M | -3.84M | -216.51M | -225.58M | -55.69M | -57.5M | -37.38M | -53.51M |
| Net Interest Income | -53.88K | -51.52K | -42.03K | 230K | 3.8M | 1.84M | -241K | 1.77M |
| Interest Income | 15.51K | 8.04K | 201 | 472K | 3.92M | 2.04M | 0 | 2.04M |
| Interest Expense | 69.39K | 59.57K | 42.23K | 242K | 119.66K | 203K | 241K | 267.63K |
| Other Income/Expense | -69.39K | -2.91M | -159.89M | -159.8M | -4.76M | -9.56M | -17.54M | -10.35M |
| Pretax Income | -20.87M▲ 0% | -3.9M▲ 81.3% | -216.55M▼ 5450.6% | -225.82M▼ 4.3% | -56.67M▲ 74.9% | -57.7M▼ 1.8% | -54.92M▲ 4.8% | -53.77M▲ 0% |
| Pretax Margin % | -226.06% | -5.99% | -1727.9% | -1715.44% | -260.63% | -188.44% | -59.45% | -77.89% |
| Income Tax | -677.47K | -1.94M | 2.57M | -245K | -269.36K | -7.87M | 40K | -7.51M |
| Effective Tax Rate % | 3.25% | 49.66% | -1.19% | 0.11% | 0.48% | 13.65% | -0.07% | 13.97% |
| Net Income | -20.14M▲ 0% | -1.94M▲ 90.4% | -174.01M▼ 8871.0% | -190.45M▼ 9.5% | -62.72M▲ 67.1% | -46.3M▲ 26.2% | -58.32M▼ 26.0% | -46.55M▲ 0% |
| Net Margin % | -218.15% | -2.98% | -1388.44% | -1446.78% | -288.48% | -151.22% | -63.13% | -67.43% |
| Net Income Growth % | - | 90.37% | -8870.99% | -9.45% | 67.07% | 26.18% | -25.96% | 0.77% |
| Net Income (Continuing) | -20.2M | -1.96M | -219.12M | -225.58M | -56.4M | -49.83M | -54.96M | -46.26M |
| Discontinued Operations | 0 | 0 | 45.11M | 35.12M | -8.38M | 22K | -5.63M | -2M |
| Minority Interest | -53.21K | -77.41K | -84.97K | 6.4M | 3.8M | 957K | -93K | -90K |
| EPS (Diluted) | -2.73▲ 0% | -0.26▲ 90.5% | -47.04▼ 17992.3% | -37.57▲ 20.1% | -5.58▲ 85.1% | -3.64▲ 34.8% | -4.15▼ 14.0% | -3.35▲ 0% |
| EPS Growth % | - | 90.48% | -17992.31% | 20.13% | 85.15% | 34.77% | -14.01% | 10.78% |
| EPS (Basic) | -2.73 | -0.26 | -47.04 | -37.57 | -5.58 | -3.64 | -4.15 | - |
| Diluted Shares Outstanding | 7.4M | 7.4M | 3.7M | 5.07M | 11.25M | 12.71M | 14.05M | 13.9M |
| Basic Shares Outstanding | 7.4M | 7.4M | 3.7M | 5.07M | 11.25M | 12.71M | 14.05M | 13.9M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
PRE Balance Sheet
Prenetics Global Limited (PRE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 15.63M | 43.96M | 106.89M | 241.81M | 93.66M | 86.15M | 83.39M | 38.28M |
| Cash & Short-Term Investments | 11.82M | 14.8M | 45.19M | 184.12M | 72.74M | 62.81M | 61.49M | 23.73M |
| Cash Only | 11.52M | 14.49M | 35.29M | 146.66M | 45.71M | 52.25M | 32.13M | 13.26M |
| Short-Term Investments | 294.06K | 314.71K | 9.91M | 37.46M | 27.03M | 10.56M | 29.36M | 10.46M |
| Accounts Receivable | 2.89M | 23.1M | 47.05M | 42.5M | 5.29M | 5.61M | 2.98M | 1.79M |
| Days Sales Outstanding | 114.34 | 129.34 | 1.37K | 1.18K | 88.87 | 66.81 | 11.78 | 38.08 |
| Inventory | 547.85K | 4.5M | 6.83M | 4.53M | 3.13M | 6.57M | 7.06M | 5.34M |
| Days Inventory Outstanding | 30.68 | 42.27 | 279.13 | 173.36 | 88.39 | 157.45 | 59.28 | 57.07 |
| Other Current Assets | 374.36K | 979.6K | 7.31M | 4.58M | 8.31M | 3.55M | 11.86M | 7.42M |
| Total Non-Current Assets | 14.06M | 34.93M | 41.61M | 70.32M | 160.51M | 127.43M | 120.13M | 158.23M |
| Property, Plant & Equipment | 2.11M | 4.69M | 13.04M | 13.1M | 5.78M | 7.81M | 1.76M | 2.21M |
| Fixed Asset Turnover | 4.37x | 13.89x | 0.96x | 1.00x | 3.76x | 3.92x | 52.40x | 13.92x |
| Goodwill | 3.85M | 3.99M | 3.98M | 33.8M | 29.17M | 37.36M | 0 | 8.19M |
| Intangible Assets | 6.27M | 23.96M | 23.83M | 14.79M | 13.43M | 11.57M | 44.7M | 170K |
| Long-Term Investments | 1.66M | 0 | 0 | 788.47K | 107.84M | 69.33M | 67M | 273.48M |
| Other Non-Current Assets | 161K | 2.28M | 693.55K | 7.6M | 4.27M | 1.35M | 6.68M | 83.32M |
| Total Assets | 29.69M▲ 0% | 78.88M▲ 165.7% | 148.51M▲ 88.3% | 312.13M▲ 110.2% | 254.17M▼ 18.6% | 213.57M▼ 16.0% | 203.52M▼ 4.7% | 196.51M▲ 0% |
| Asset Turnover | 0.31x | 0.83x | 0.08x | 0.04x | 0.09x | 0.14x | 0.45x | 0.34x |
| Asset Growth % | - | 165.72% | 88.26% | 110.18% | -18.57% | -15.97% | -4.71% | -63.53% |
| Total Current Liabilities | 11.9M | 47.07M | 58.74M | 57.2M | 39.48M | 36.55M | 27.67M | 25.28M |
| Accounts Payable | 2.76M | 13.44M | 9.98M | 7.29M | 1.67M | 3.67M | 7.72M | 5.92M |
| Days Payables Outstanding | 154.61 | 126.29 | 407.9 | 278.78 | 47.23 | 87.96 | 64.9 | 46.74 |
| Short-Term Debt | 0 | 15.47M | 1.67M | 0 | 0 | 0 | 1.33M | 1.43M |
| Deferred Revenue (Current) | 0 | 0 | 9.59M | 5.67M | 6.11M | 6.49M | 3.09M | 26.51M |
| Other Current Liabilities | 7.79M | 10.92M | 22.64M | 17.47M | 15.49M | 15.07M | 15.5M | 10.73M |
| Current Ratio | 1.31x | 0.93x | 1.82x | 4.23x | 2.37x | 2.36x | 3.01x | 3.01x |
| Quick Ratio | 1.27x | 0.84x | 1.70x | 4.15x | 2.29x | 2.18x | 2.76x | 2.76x |
| Cash Conversion Cycle | -9.6 | 45.32 | 1.24K | 1.07K | 130.03 | 136.31 | 6.16 | 48.41 |
| Total Non-Current Liabilities | 930.56K | 804.57K | 490.66M | 11.47M | 4.53M | 5.68M | 1.34M | 10.03M |
| Long-Term Debt | 124.32K | 0 | 486.4M | 0 | 0 | 0 | 437K | 0 |
| Capital Lease Obligations | 775.23K | 804.57K | 3.6M | 3.76M | 867K | 3.01M | 437K | 7.29M |
| Deferred Tax Liabilities | 0 | 0 | 659.5K | 3.19M | 2.62M | 2.17M | 8K | 4.27M |
| Other Non-Current Liabilities | 31.01K | 0 | 0 | 4.52M | 1.05M | 499K | 460K | 11.51M |
| Total Liabilities | 12.83M | 47.88M | 549.4M | 68.67M | 44.01M | 42.23M | 29.01M | 35.3M |
| Total Debt | 1.46M | 17.14M | 491.67M | 6.65M | 2.37M | 5.77M | 2.2M | 2.1M |
| Net Debt | -10.07M | 2.65M | 456.38M | -140.01M | -43.34M | -46.48M | -29.93M | -11.16M |
| Debt / Equity | 0.09x | 0.55x | - | 0.03x | 0.01x | 0.03x | 0.01x | 0.01x |
| Debt / EBITDA | - | 11.98x | - | - | - | - | - | -0.04x |
| Net Debt / EBITDA | - | 1.86x | - | - | - | - | - | 0.21x |
| Interest Coverage | -299.80x | -16.71x | -1341.78x | -272.82x | -433.78x | -237.16x | -155.12x | -199.93x |
| Total Equity | 16.85M▲ 0% | 31.01M▲ 84.0% | -400.89M▼ 1392.9% | 243.46M▲ 160.7% | 210.16M▼ 13.7% | 171.35M▼ 18.5% | 174.51M▲ 1.8% | 161.2M▲ 0% |
| Equity Growth % | - | 83.99% | -1392.92% | 160.73% | -13.68% | -18.47% | 1.85% | -70.5% |
| Book Value per Share | 2.28 | 4.19 | -108.37 | 48.03 | 18.69 | 13.49 | 12.42 | 11.60 |
| Total Shareholders' Equity | 16.91M | 31.08M | -400.81M | 237.06M | 206.36M | 170.39M | 174.6M | 161.29M |
| Common Stock | 45.69M | 15.35M | 1.49K | 13.7K | 18K | 19K | 25K | 21K |
| Retained Earnings | -41.64M | -43.58M | 0 | -408.04M | -470.77M | -517.07M | 0 | 0 |
| Treasury Stock | 0 | 0 | 0 | -661.52K | -62K | -639K | 0 | 0 |
| Accumulated OCI | 12.86M | 21.42M | -400.81M | -185.69M | -176.03M | -169.25M | 0 | 161.27M |
| Minority Interest | -53.21K | -77.41K | -84.97K | 6.4M | 3.8M | 957K | -93K | -90K |
PRE Cash Flow Statement
Prenetics Global Limited (PRE) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.88M | -2.88M | 13.42M | 14.51M | -13.76M | -28.87M | -21.81M | -21.81M |
| Operating CF Margin % | -20.4% | -4.42% | 107.05% | 110.26% | -63.31% | -94.29% | -23.61% | - |
| Operating CF Growth % | - | -52.92% | 565.9% | 8.18% | -194.84% | -109.77% | 24.46% | 0% |
| Net Income | -20.2M | -1.96M | -174.02M | -190.45M | -64.78M | -49.81M | -52.7M | -46.55M |
| Depreciation & Amortization | 2.23M | 2.43M | 7.35M | 7.54M | 7.79M | 5.93M | 3.78M | 0 |
| Stock-Based Compensation | 3.91M | 1.62M | 22.49M | 31.58M | 10.59M | 11.98M | 0 | 5.97M |
| Deferred Taxes | -677.47K | -1.94M | 3.73M | 7.15M | -385.84K | -7.87M | 0 | 0 |
| Other Non-Cash Items | 2.64M | 4.77M | 160.45M | 192.46M | 8.8M | 8.93M | 20.48M | 40.58M |
| Working Capital Changes | 10.21M | -7.79M | -6.59M | -33.76M | 24.21M | 1.97M | 6.62M | 0 |
| Change in Receivables | 1.83M | -20.09M | -24.06M | 6.97M | 37.63M | -428K | -529K | 0 |
| Change in Inventory | 415.69K | -3.75M | -2.33M | 1.26M | -1.73M | 1.32M | -3.38M | 0 |
| Change in Payables | 1.71M | 9.71M | -3.46M | -2.63M | -5.62M | -4.68M | 4.91M | 0 |
| Cash from Investing | -4.6M | -5.97M | -22.02M | -46.14M | -82.95M | 38.54M | -35.79M | 0 |
| Capital Expenditures | -373.86K | -3.06M | -8.55M | -6.34M | -345.29K | -1.01M | -54.56M | 0 |
| CapEx % of Revenue | 4.05% | 4.69% | 68.2% | 48.18% | 1.59% | 3.29% | 59.06% | - |
| Acquisitions | -4.24M | -2.93M | 0 | -3.42M | 0 | 21.65M | 37.77M | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 12.43K | 14.75K | -3.47M | 531.99K | -76.52M | 2.02M | 1000K | 0 |
| Cash from Financing | -569.14K | 11.84M | 29.32M | 143.32M | -4.7M | -3.34M | 37.54M | 0 |
| Debt Issued (Net) | -503.58K | -610.93K | -1.3M | -1.88M | -3.23M | -2.56M | 40.15M | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | -661.52K | -1000K | -577K | 2K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -661.52K | -1.23M | -577K | 0 | 0 |
| Other Financing | -65.55K | 12.45M | 4.65M | 145.86M | -241.5K | -203K | -2.61M | 0 |
| Net Change in Cash | -7.26M▲ 0% | 2.97M▲ 140.9% | 20.8M▲ 600.7% | 111.37M▲ 435.5% | -100.95M▼ 190.6% | 6.54M▲ 106.5% | -20.12M▼ 407.4% | 0▲ 0% |
| Free Cash Flow | -2.26M▲ 0% | -5.94M▼ 163.2% | 2M▲ 133.7% | 8.17M▲ 307.7% | -14.68M▼ 279.6% | -29.94M▼ 104.0% | -22.02M▲ 26.5% | 0▲ 0% |
| FCF Margin % | -24.44% | -9.11% | 15.99% | 62.08% | -67.5% | -97.77% | -23.83% | - |
| FCF Growth % | - | -163.17% | 133.74% | 307.73% | -279.6% | -103.99% | 26.45% | - |
| FCF per Share | -0.31 | -0.80 | 0.54 | 1.61 | -1.31 | -2.36 | -1.57 | -1.57 |
| FCF Conversion (FCF/Net Income) | 0.09x | 1.48x | -0.08x | -0.08x | 0.22x | 0.62x | 0.37x | -0.00x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRE Key Ratios
Prenetics Global Limited (PRE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -8.11% | - | -78.23% | -27.65% | -24.27% | -33.73% | -28.88% |
| Return on Invested Capital (ROIC) | -3.69% | -95.34% | -62.31% | -28.81% | -24.76% | -20.81% | -20.81% |
| Gross Margin | 40.42% | 28.75% | 27.48% | 40.61% | 50.29% | 52.98% | 47.16% |
| Net Margin | -2.98% | -1388.44% | -1446.78% | -288.48% | -151.22% | -63.13% | -67.43% |
| Debt / Equity | 0.55x | - | 0.03x | 0.01x | 0.03x | 0.01x | 0.01x |
| Interest Coverage | -16.71x | -1341.78x | -272.82x | -433.78x | -237.16x | -155.12x | -199.93x |
| FCF Conversion | 1.48x | -0.08x | -0.08x | 0.22x | 0.62x | 0.37x | -0.00x |
| Revenue Growth | 605.93% | -80.77% | 5.04% | 65.17% | 40.83% | 201.72% | 171.69% |
PRE Frequently Asked Questions
Prenetics Global Limited (PRE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Prenetics Global Limited (PRE) reported $69.0M in revenue for fiscal year 2025. This represents a 648% increase from $9.2M in 2019.
Prenetics Global Limited (PRE) grew revenue by 201.7% over the past year. This is strong growth.
Prenetics Global Limited (PRE) reported a net loss of $46.5M for fiscal year 2025.
Dividend & Returns
Prenetics Global Limited (PRE) has a return on equity (ROE) of -33.7%. Negative ROE indicates the company is unprofitable.
Prenetics Global Limited (PRE) had negative free cash flow of $22.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More PRE
Prenetics Global Limited (PRE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates